NMTC

NeuroOne Medical Technologies Corporation

1.56 USD

Last updated Sep 12, 02:17 UTC

Yesterday HIGH

$1.67

Yesterday LOW

$1.56

52w HIGH

$6.96

52w LOW

$1.42

EPS

-0.28

PE

-5.57

Next Earnings

Dec 16, 2026

Overview News Insider Transactions Government Trades Fundamentals

NeuroOne Medical Technologies Corporation stock is down -14.75% since 30 days ago. The next earnings date is Dec 16, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 13 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Thu Aug 27, 2026

NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter

Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in
Benzinga Newsdesk

Fri Aug 14, 2026

Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5

Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.
Benzinga Newsdesk

Fri May 22, 2026

NeuroOne Medical Technologies To Restate Q1 2026 Financial Statements; Restatement Corrects $0.5M Revenue Overstatement For Q1 2026; Net Loss Understated By $0.3M For Q1 2026; Restatement Does Not Affect Fy2026 Product Revenue Guidance Or Cash Position

-SEC Filing
Benzinga Insights

Tue May 19, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights

Tue May 12, 2026

NeuroOne Medical Tech Q2 2026 Earnings Call Transcript
Benzinga Newsdesk

Tue May 12, 2026

NeuroOne Medical Tech Q2 EPS $(0.25) Misses $(0.23) Estimate, Sales $2.391M Miss $2.576M Estimate

NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 40.48 percent increase over losses of $(0.42) per share
Benzinga Insights

Tue May 12, 2026

Earnings Scheduled For May 12, 2026
Benzinga Newsdesk

Thu Apr 16, 2026

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Wed Apr 15, 2026

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Benzinga Insights

Wed Apr 8, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session

Maxim Group

Fri Aug 14, 22:21

buy

confirm

Advanced Data Unlock

David Wambeke, Chief Business Officer

Fri Aug 28, 2026

NMTC Recent Insider Trades and Stock Chart

35,000 shares awarded
Emily Johns, Chief Administrative Officer

Fri Aug 28, 2026

NMTC Recent Insider Trades and Stock Chart

12,500 shares awarded
Christopher Volker, Chief Financial Officer

Fri Aug 28, 2026

NMTC Recent Insider Trades and Stock Chart

35,000 shares awarded
Mark Christianson, Market Development Director

Fri Aug 28, 2026

NMTC Recent Insider Trades and Stock Chart

12,500 shares awarded
Steve Mertens, Chief Technology Officer

Fri Aug 28, 2026

NMTC Recent Insider Trades and Stock Chart

15,000 shares awarded
David Rosa, CEO & President

Fri Aug 28, 2026

NMTC Recent Insider Trades and Stock Chart

68,000 shares awarded
David Wambeke, Chief Business Officer

Thu Aug 27, 2026

NMTC Recent Insider Trades and Stock Chart

33,333 shares bought